Dupilumab Use in Severe Epidermolysis Bullosa Simplex | Synapse
February 27, 2026
Dupilumab Use in Severe Epidermolysis Bullosa Simplex
Key Points
The aim is to evaluate the effects of dupilumab in an infant with severe epidermolysis bullosa simplex.
Case report of an infant patient
Assessment of treatment response to dupilumab
Monitoring for adverse effects
Improvement in skin condition observed
Reduction in blister formation noted
No significant adverse effects reported
Abstract
This case report describes treatment with dupilumab in an infant patient with generalized severe epidermolysis bullosa simplex due to a pathogenic variant.